Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study

Authors: Yun Shin Chun, Min Huang, Lori Rink, Margaret Von Mehren

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

The insulin-like growth factor (IGF) pathway is implicated in the pathogenesis of hepatocellular carcinoma (HCC) and may be important in nonalcoholic fatty liver disease (NAFLD). The aim of this study is to determine expression levels of IGFs and receptors in NAFLD-associated HCC.

Methods

Tissue microarrays were constructed from patients who underwent hepatectomy for HCC. Immunohistochemistry was performed using antibodies for IGF ligands and receptors. Immunostain results were scored by a pathologist blinded to clinical data.

Results

Among 27 patients with HCC, the most common underlying liver diseases included NAFLD, hepatitis C, and alcoholic hepatitis. Expression levels of IGFs and receptors were not associated with patients’ underlying liver disease. In all patients, IGF-2 expression was upregulated in tumor and adjacent non-neoplastic liver. Expression of IGF-1 was low in adjacent liver in 6 of 10 patients with cirrhosis, compared with 2 of 17 patients without cirrhosis (P = 0.025). Higher IGF-1 expression in liver adjacent to tumor was associated with poorer median survival of 22 months, compared with 72 months with equal or lower IGF-1 expression in adjacent liver relative to tumor (P = 0.006).

Conclusions

Our preliminary results demonstrate significant associations between IGF-1 expression and liver cirrhosis and survival after resection in patients with HCC, independent of their underlying liver disease.
Appendix
Available only for authorised users
Literature
2.
go back to reference Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ: Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med. 2008, 132: 1761-1766.PubMed Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ: Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med. 2008, 132: 1761-1766.PubMed
3.
go back to reference Breuhahn K, Longerich T, Schirmacher P: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006, 25: 3787-3800.CrossRefPubMed Breuhahn K, Longerich T, Schirmacher P: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006, 25: 3787-3800.CrossRefPubMed
4.
go back to reference Baffy G, Brunt EM, Caldwell SH: Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012, 56: 1384-1391.CrossRefPubMed Baffy G, Brunt EM, Caldwell SH: Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012, 56: 1384-1391.CrossRefPubMed
5.
go back to reference Torres DM, Harrison SA: Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis. 2012, 32: 30-38.CrossRefPubMed Torres DM, Harrison SA: Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis. 2012, 32: 30-38.CrossRefPubMed
6.
go back to reference Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, Neff GW, Rosemurgy AS, Alsina AE: Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford). 2013, 15: 504-510.CrossRef Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, Neff GW, Rosemurgy AS, Alsina AE: Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford). 2013, 15: 504-510.CrossRef
7.
go back to reference Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004, 4: 579-591.CrossRefPubMed Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004, 4: 579-591.CrossRefPubMed
8.
go back to reference Scharf JG, Braulke T: The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res. 2003, 35: 685-693.CrossRefPubMed Scharf JG, Braulke T: The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res. 2003, 35: 685-693.CrossRefPubMed
9.
10.
go back to reference Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, Lu KH: Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004, 13: 748-752.PubMed Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, Lu KH: Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004, 13: 748-752.PubMed
11.
go back to reference Ryan PD, Goss PE: The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 2008, 13: 16-24.CrossRefPubMed Ryan PD, Goss PE: The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 2008, 13: 16-24.CrossRefPubMed
12.
go back to reference Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012, 12: 159-169.PubMed Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012, 12: 159-169.PubMed
13.
go back to reference Sedlaczek N, Hasilik A, Neuhaus P, Schuppan D, Herbst H: Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer. 2003, 88: 733-739.PubMedCentralCrossRefPubMed Sedlaczek N, Hasilik A, Neuhaus P, Schuppan D, Herbst H: Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer. 2003, 88: 733-739.PubMedCentralCrossRefPubMed
14.
go back to reference Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA. 2008, 105: 8387-8392.PubMedCentralCrossRefPubMed Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA. 2008, 105: 8387-8392.PubMedCentralCrossRefPubMed
15.
go back to reference Belinsky MG, Rink L, Cai KQ, Ochs MF, Eisenberg B, Huang M, von Mehren M, Godwin AK: The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle. 2008, 7: 2949-2955.PubMedCentralCrossRefPubMed Belinsky MG, Rink L, Cai KQ, Ochs MF, Eisenberg B, Huang M, von Mehren M, Godwin AK: The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle. 2008, 7: 2949-2955.PubMedCentralCrossRefPubMed
16.
go back to reference Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 2010, New York: Springer Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 2010, New York: Springer
17.
go back to reference Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y: Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol. 2008, 49: 34-42.CrossRefPubMed Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y: Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol. 2008, 49: 34-42.CrossRefPubMed
18.
19.
go back to reference Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL: Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011, 29: 3892-3899.PubMedCentralCrossRefPubMed Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL: Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011, 29: 3892-3899.PubMedCentralCrossRefPubMed
20.
go back to reference Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, Ullrich A, Brechot C: Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 1988, 48: 6844-6849.PubMed Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, Ullrich A, Brechot C: Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 1988, 48: 6844-6849.PubMed
21.
go back to reference Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P, Breuhahn K: Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology. 2008, 48: 146-156.CrossRefPubMed Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P, Breuhahn K: Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology. 2008, 48: 146-156.CrossRefPubMed
22.
go back to reference Park BC, Huh MH, Seo JH: Differential expression of transforming growth factor a and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma. J Hepatol. 1995, 22: 286-294.CrossRefPubMed Park BC, Huh MH, Seo JH: Differential expression of transforming growth factor a and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma. J Hepatol. 1995, 22: 286-294.CrossRefPubMed
23.
go back to reference Cantarini MC, de la Monte SM, Pang M, Tong M, D’Errico A, Trevisani F, Wands JR: Aspartyl-asparagyl β hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006, 44: 446-457.CrossRefPubMed Cantarini MC, de la Monte SM, Pang M, Tong M, D’Errico A, Trevisani F, Wands JR: Aspartyl-asparagyl β hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006, 44: 446-457.CrossRefPubMed
Metadata
Title
Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study
Authors
Yun Shin Chun
Min Huang
Lori Rink
Margaret Von Mehren
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-231

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue